Clinical Trial Update: Treating Multiple Sclerosis With Sirolimus, an Immune System Suppressor [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial of sirolimus for relapsing-remitting multiple sclerosis has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Rapamune (sirolimus)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Multiple Sclerosis (MS) - Relapsing-remitting | Phase 1, Phase 2 | Status: TERMINATED